Floatz logo

Ifinatamab Deruxtecan

Neuroendocrine Carcinoma

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)antibody_drug_conjugatePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

49 Active assets in the Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B
Everolimus
AIO-Studien-gGmbH
Phase 2B
Carboplatin
Phanes Therapeutics
Phase 2B
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 2B

View all 50 →

Same molecule, other indications

Ifinatamab Deruxtecan is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
Recurrent or Metastatic Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →